Noiiglutide
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
Hengrui · Phase 2 · Completed · Enrollment 128
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HS-20004 or placebo treatment (Low dose) | n/r | n/r | n/r | n/r |
| HS-20004 or placebo treatment (median dose 1) | n/r | n/r | n/r | n/r |
| HS-20004 or placebo treatment (median dose 2) | n/r | n/r | n/r | n/r |
| HS-20004 or placebo treatment (high dose) | n/r | n/r | n/r | n/r |
Not shown
- HS-20004 or placebo treatment (Low dose): endpoint not reported
- HS-20004 or placebo treatment (median dose 1): endpoint not reported
- HS-20004 or placebo treatment (median dose 2): endpoint not reported
- HS-20004 or placebo treatment (high dose): endpoint not reported